Developed in collaboration with Brainlab, Stimview XT offers real-time, 3D visualisation and stimulation of brain anatomy for deep brain stimulation therapy
Stimview XT offers real-time, 3D visualisation and stimulation of the brain anatomy. (Credit: Boston Scientific Corporation)
US-based medical devices maker Boston Scientific announced the US Food and Drug Administration (FDA) approval for its latest image-guided programming software, Vercise Neural Navigator with Stimview XT.
Developed in collaboration with Brainlab, Stimview XT offers real-time, 3D visualisation and stimulation of the brain anatomy of a patient with Parkinson’s disease or essential tremor.
Stimview XT when used along with the Vercise Genus deep brain stimulation (DBS) portfolio is said to be the most advanced and integrated visualisation software for DBS programming.
The software allows clinicians to use patient-specific 3D imaging to customise the therapy to match the needs of each patient.
It intends to aid in locating the lead placement, save programming time, and enable more informed treatment decisions by smoothly integrating into the Vercise Genus programming interface, said Boston Scientific.
University of California Movement Disorders and Neuromodulation Center medical director Jill Ostrem said: “It’s exciting that clinicians will now have access to more sophisticated image-guided programming tools supporting personalized DBS therapy.
“This advancement with Stimview XT may also save time for the clinician as it could help avoid the trial and error in finding the precise location. Prolonged periods of time in adjusting stimulation settings can be stressful and tiring for patients.”
Boston Scientific neuromodulation senior vice president Maulik Nanavaty said: “Every person’s experience living with Parkinson’s disease or essential tremor is unique, and their treatment should be as unique.
“Our technologies enable clinicians to precisely see, shape, and steer DBS therapy to meet their patients’ individual needs. This latest advancement is a testament to how we’ll continue to deliver on meaningful innovations that support doctors.”
The company said that the launch of Vercise Neural Navigator with Stimview XT in the US follows the release of the programme in Europe, giving doctors more access to patients suffering from Parkinson’s disease or essential tremor.